Bihua Chen
Sits on 5 boards. Overboarded · 5 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 5 boards, counting each seat separately. Longest: Biomea Fusion Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
BridgeBio Oncology Therapeutics Inc. August 4, 2025100.0%
-
Biomea Fusion Inc. June 11, 202573.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | BlossomHill Therapeutics Inc. | Derivative conversion | +1,599,993 | — | — |
| Aug 10, 2026 | BlossomHill Therapeutics Inc. | Derivative conversion | +1,701,541 | — | — |
| Aug 10, 2026 | BlossomHill Therapeutics Inc. | Open-market purchase | +312,500 | $16.00 | $5,000,000 |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | −4,528,186 | — | — |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | +2,692,459 | — | — |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | +1,704,862 | — | — |
| Jul 1, 2026 | BridgeBio Oncology Therapeutics Inc. | Other | +130,865 | — | — |
| Jan 26, 2026 | Helix Acquisition Corp. III | Grant or award | +497,500 | $10.00 | $4,975,000 |
| Dec 11, 2025 | Corbus Pharmaceuticals Holdings Inc. | Open-market sale | −30,029 | $11.46 | $344,132 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Option exercise | +4,172,126 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Sold back to the company | −152,940 | — | — |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +760,496 | $10.72 | $8,152,517 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +639,110 | $10.72 | $6,851,259 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +5,598,425 | $10.72 | $60,015,116 |
| Aug 11, 2025 | BridgeBio Oncology Therapeutics Inc. | Grant or award | +1,905,046 | — | — |
Questions about Bihua Chen
What boards is Bihua Chen on?
Bihua Chen sits on the boards of Biomea Fusion Inc., BlossomHill Therapeutics Inc., BridgeBio Oncology Therapeutics Inc., Erasca Inc. and Helix Acquisition Corp. III.
What company is Bihua Chen the CEO of?
Bihua Chen has been Chairperson and CEO of Helix Acquisition Corp. III since January 2026.
How long has Bihua Chen served on boards?
Our records show at least 11 years of board service across 5 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.